| Autor: |
Faraoni EY; Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina., Abeledo Machado AI; Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina., Pérez PA; Centro de Microscopia Electrónica, Instituto de Investigaciones en Ciencias de la Salud (INICSA-CONICET), Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina., Marcial López CA; Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina., Camilletti MA; Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina., Peña-Zanoni M; Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina., Rulli SB; Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina., Gutiérrez S; Centro de Microscopia Electrónica, Instituto de Investigaciones en Ciencias de la Salud (INICSA-CONICET), Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina., Díaz-Torga G; Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina. |
| Abstrakt: |
Among all the hormone-secreting pituitary tumours, prolactinomas are the most frequently found in the clinic. Since dopamine is the primary inhibitor of lactotroph function, dopamine agonists represent the first-line therapy. However, a subset of patients exhibits resistance to these drugs, and therefore, alternative treatments are desired. As activins inhibit prolactin gene expression through the inhibition of Pit-1 involving the p38MAPK pathway, in the present work, we studied the local activin system as an alternative inhibitory system for lactotroph hyperplasia treatment. We used two different mouse models of prolactinoma: transgenic mice with overexpression of the human chorionic gonadotropin β-subunit (hCGβ) and mice lacking dopamine receptor type 2. In both models, females, but not males, develop lactotroph hyperplasia from the fourth month of life. We found reduced expression of pituitary activin subunits and activin receptors in hyperplastic pituitaries from both models compared with wild-type counterparts. Consequently, hyperplastic pituitaries presented a reduced activin-inhibitory action on prolactin secretion. Additionally, while female wild-type lactotrophs presented high levels of phospho-p38MAPK, it was lost in prolactinomas, concomitant with decreased activin expression, increased Pit-1 expression and tumour development. In contrast, male pituitaries express higher mRNA levels of activin subunits βA and βB, which would suggest a stronger activin inhibitory function on lactotrophs, protecting this sex from tumour development, despite genotype. The present results highlight the importance of the activin inhibitory action on lactotroph function and place the local activin system as a new target for the treatment of dopamine agonist-resistant prolactinomas. |
